>
Zelira Therapeutics logo

ZLD - Zelira Therapeutics Share Price

A$0.048 0.0  2.1%

Last Trade - 6:19am

Sector
Healthcare
Size
Micro Cap
Market Cap £30.7m
Enterprise Value £26.2m
Revenue £862k
Position in Universe 1085th / 1913
Bullish
Bearish
Unlock ZLD Revenue
Momentum
Relative Strength (%)
1m -24.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -66.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.012 0.003 0.17 0.56 0.86 1.04 4.80 24.4 +145.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ZeliraTherapeutics Ltd revenues increased 52% to A$1.5M. Net lossincreased 40% to A$3.6M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsDirector and employee expenses increase from A$366K toA$1.3M (expense), Share based payments increase from A$177Kto A$504K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZLD Revenue Unlock ZLD Revenue

Net Income

ZLD Net Income Unlock ZLD Revenue

Normalised EPS

ZLD Normalised EPS Unlock ZLD Revenue

PE Ratio Range

ZLD PE Ratio Range Unlock ZLD Revenue

Dividend Yield Range

ZLD Dividend Yield Range Unlock ZLD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZLD EPS Forecasts Unlock ZLD Revenue
Profile Summary

Zelira Therapeutics Ltd, formerly Zelda Therapeutics Ltd, is an Australia-based therapeutic medicinal cannabis company. The company is focused on developing cannabis products for the treatment of a variety of medical conditions. It is focused on human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. It is also focused on pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. It develops treatments based on plant-derived medicinal cannabis products.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated February 18, 2003
Public Since July 28, 2003
No. of Shareholders: 9,098
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,185,322,966
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZLD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZLD
Upcoming Events for ZLD
Thursday 11th November, 2021 Estimate
Zelira Therapeutics Ltd Annual Shareholders Meeting
Frequently Asked Questions for Zelira Therapeutics
What is the Zelira Therapeutics share price?

As of 6:19am, shares in Zelira Therapeutics are trading at A$0.048, giving the company a market capitalisation of £30.7m. This share price information is delayed by 15 minutes.

How has the Zelira Therapeutics share price performed this year?

Shares in Zelira Therapeutics are currently trading at A$0.048 and the price has moved by 2.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zelira Therapeutics price has moved by -21.74% over the past year.

What are the analyst and broker recommendations for Zelira Therapeutics?

There are no analysts currently covering Zelira Therapeutics.

When will Zelira Therapeutics next release its financial results?

Zelira Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Zelira Therapeutics dividend yield?

Zelira Therapeutics does not currently pay a dividend.

Does Zelira Therapeutics pay a dividend?

Zelira Therapeutics does not currently pay a dividend.

When does Zelira Therapeutics next pay dividends?

Zelira Therapeutics does not currently pay a dividend.

How do I buy Zelira Therapeutics shares?

To buy shares in Zelira Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zelira Therapeutics?

Shares in Zelira Therapeutics are currently trading at A$0.048, giving the company a market capitalisation of £30.7m.

Where are Zelira Therapeutics shares listed? Where are Zelira Therapeutics shares listed?

Here are the trading details for Zelira Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ZLD
What kind of share is Zelira Therapeutics?

Based on an overall assessment of its quality, value and momentum, Zelira Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zelira Therapeutics share price forecast 2021?

Shares in Zelira Therapeutics are currently priced at A$0.048. At that level they are trading at 0.198% discount to the analyst consensus target price of 0.00.

Analysts covering Zelira Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.002 for the next financial year.

How can I tell whether the Zelira Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zelira Therapeutics. Over the past six months, the relative strength of its shares against the market has been -36.85%. At the current price of A$0.048, shares in Zelira Therapeutics are trading at -34.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zelira Therapeutics PE Ratio?

We were not able to find PE ratio data for Zelira Therapeutics.

Who are the key directors of Zelira Therapeutics?

Zelira Therapeutics's management team is headed by:

Leon Davies - NED
Harry Karelis - VCH
Tim Slate - SEC
Richard Hopkins - CEO
Lisa Gray - DRC
Osagie Imasogie - CHM
Oludare Odumosu - MDR
Jason Peterson - DRC
Who are the major shareholders of Zelira Therapeutics?

Here are the top five shareholders of Zelira Therapeutics based on the size of their shareholding:

Sunset Capital Management Pty. Ltd. Corporation
Percentage owned: 4.66% (55.4m shares)
TIGA Trading Pty Ltd Investment Advisor
Percentage owned: 4.6% (54.7m shares)
Karelis (Harry) Individual Investor
Percentage owned: 4.17% (49.6m shares)
Gordon (Mara) Individual Investor
Percentage owned: 3.71% (44.1m shares)
Washer (Stewart James) Individual Investor
Percentage owned: 2.96% (35.2m shares)
Similar to ZLD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.